Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ceribell, Inc.CBLL · Entity 4994 | Director | June 02, 2026 | June 04, 2026 |
| Lucira Health, Inc.LHDX · Entity 115613 | Director | June 01, 2022 | June 03, 2022 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Director | June 05, 2025 | June 10, 2025 |
| Silk Road Medical IncSILK · Entity 87417 | Director · President and CEO | March 02, 2021 | September 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ceribell, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,054 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,838 · Balance 33,054 F1: Represents restricted stock units ("RSUs"). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs").
Lucira Health, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-05-31 | Direct | 59,459 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 59,459 · Balance 59,459 F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting.
Sight Sciences, Inc.
Report date June 05, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,352 |
Reported balance
After 2025-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 30,952 · Balance 175,352 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $130,000 divided by the closing price of the Common Stock on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs, which are subject to vesting as reported herein, and (iii) 100,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $130,000 divided by the closing price of the Common Stock on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.
F2: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs, which are subject to vesting as reported herein, and (iii) 100,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025.
Silk Road Medical Inc
Report date March 02, 2021 · Filed September 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 267,988 |
Reported balance
After 2021-03-02 transaction · row 1
1 source rowRow 1 · 2021-03-02 · Sale · Disposed 1,651 · Balance 267,988 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F2: This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F2: This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 4, 2026 21:08 UTC | Ceribell, Inc. CBLL · Entity 4994 | GrantCommon Stock | 7,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-257731 · ownership.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,054 F1 · shares: Represents restricted stock units ("RSUs"). Read SEC document |
| September 17, 2025 Filed Sep 20, 2025 01:14 UTC | Ceribell, Inc. CBLL · Entity 4994 | GrantCommon Stock | 25,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-209534 · ownership.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,216 F1 · shares: Represents 25,216 restricted stock units. F1 · balance_after: Represents 25,216 restricted stock units. Read SEC document |
| June 05, 2025 Filed Jun 10, 2025 01:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 30,952 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084072 · ownership.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,352 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $130,000 divided by the closing price of the Common Stock on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs, which are subject to vesting as reported herein, and (iii) 100,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 17,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071515 · ownership.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,876 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $120,000 divided by the closing price of the Common Stock on the grant date, June 6, 2024. The RSUs vest on the earlier of June 6, 2025 and the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 15,094 shares of Common Stock, (ii) 17,366 RSUs, which are subject to vesting as reported herein, and (iii) 95,416 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 6, 2024. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 18:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 1,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-001120 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,654 Underlying: Common Stock · 1,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F3 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 18:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 1,000 | $31.56 | $31,560.00 |
DisclosureSEC source: 0001593968-23-001120 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,639 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 18:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 1,000 | $1.60 | $1,600.00 |
DisclosureSEC source: 0001593968-23-001120 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:13 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 1,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000992 · primary_01.xml · derivative · entry 5 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,654 Underlying: Common Stock · 1,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F4 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:13 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 1,000 | $32.13 | $32,130.00 |
DisclosureSEC source: 0001593968-23-000992 · primary_01.xml · nonDerivative · entry 3 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,639 F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:13 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 1,000 | $1.60 | $1,600.00 |
DisclosureSEC source: 0001593968-23-000992 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:51 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 15,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015392 · doc4.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,356 F3 · shares: Reflects a grant of RSUs made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of Common Stock. The number of RSUs granted is equal to approximately $120,000 of shares of Common Stock as determined by the closing price on the grant date, June 8, 2023. The RSUs vest on the earlier of June 8, 2024 and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) the 11,940 shares of Common Stock issued upon the vesting of the RSUs reported on this Form 4 and (ii) 75,416 shares of Common Stock the Reporting Person has the right to acquire upon the vesting of stock options within 60 days of June 8, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:51 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015392 · doc4.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,356 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person on June 8, 2022 under the Issuer's Non-Employee Director Compensation Program, as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on August 5, 2022. Each RSU represented a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The RSUs vested in full on June 8, 2023. F2 · balance_after: Includes (i) the 11,940 shares of Common Stock issued upon the vesting of the RSUs reported on this Form 4 and (ii) 75,416 shares of Common Stock the Reporting Person has the right to acquire upon the vesting of stock options within 60 days of June 8, 2023. Read SEC document |
| May 19, 2023 Filed Jun 13, 2023 20:13 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 507 | $26.17 | $13,268.19 |
DisclosureSEC source: 0001593968-23-000992 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,639 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 1,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · derivative · entry 7 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,654 Underlying: Common Stock · 1,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F3 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · derivative · entry 6 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,654 Underlying: Common Stock · 2,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F3 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 2,000 | $35.51 | $71,020.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · nonDerivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,132 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 1,000 | $35.51 | $35,510.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · nonDerivative · entry 3 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,132 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 2,000 | $1.60 | $3,200.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 1,000 | $1.60 | $1,600.00 |
DisclosureSEC source: 0001593968-23-000796 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:29 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000601 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,654 Underlying: Common Stock · 6,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F4 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:29 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 6,000 | $39.77 | $238,635.00 |
DisclosureSEC source: 0001593968-23-000601 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,132 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F2 · price: This transaction was executed in multiple trades at price ranging from $39.12 to $40.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:29 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 6,000 | $1.60 | $9,600.00 |
DisclosureSEC source: 0001593968-23-000601 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 8, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 18:16 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000485 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,654 Underlying: Common Stock · 6,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 18:16 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 6,000 | $42.23 | $253,392.60 |
DisclosureSEC source: 0001593968-23-000485 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,132 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F2 · price: This transaction was executed in multiple trades at price ranging from $41.50 to $43.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 18:16 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 6,000 | $1.60 | $9,600.00 |
DisclosureSEC source: 0001593968-23-000485 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 20:14 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 18,043 | $47.10 | $849,901.08 |
DisclosureSEC source: 0001593968-23-000426 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,132 F2 · shares: Represents shares that have been sold by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:14 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 40,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-000426 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,175 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the shares shall vest on March 1, 2024 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 18:18 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000323 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,654 Underlying: Common Stock · 6,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 18:18 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 6,000 | $50.94 | $305,627.40 |
DisclosureSEC source: 0001593968-23-000323 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F2 · price: This transaction was executed in multiple trades at price ranging from $50.19 to $51.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 18:18 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 6,000 | $1.60 | $9,600.00 |
DisclosureSEC source: 0001593968-23-000323 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 17:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-23-000140 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,654 Underlying: Common Stock · 6,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 17:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 6,000 | $51.53 | $309,180.00 |
DisclosureSEC source: 0001593968-23-000140 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 17:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 6,000 | $1.60 | $9,600.00 |
DisclosureSEC source: 0001593968-23-000140 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:04 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001729 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,654 Underlying: Common Stock · 10,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:04 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 10,000 | $53.85 | $538,501.00 |
DisclosureSEC source: 0001593968-22-001729 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F2 · price: This transaction was executed in multiple trades at price ranging from $53.17 to $54.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:04 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001593968-22-001729 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 18:27 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001599 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,654 Underlying: Common Stock · 10,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 18:27 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 10,000 | $50.03 | $500,309.00 |
DisclosureSEC source: 0001593968-22-001599 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. F2 · price: This transaction was executed in multiple trades at price ranging from $48.44 to $51.16. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 18:27 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001593968-22-001599 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001523 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,654 Underlying: Common Stock · 10,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 10,000 | $42.32 | $423,218.00 |
DisclosureSEC source: 0001593968-22-001523 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F2 · price: This transaction was executed in multiple trades at price ranging from $40.71 to $43.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001593968-22-001523 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 19:51 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001437 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,654 Underlying: Common Stock · 10,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 19:51 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 10,000 | $43.62 | $436,173.00 |
DisclosureSEC source: 0001593968-22-001437 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F2 · price: This transaction was executed in multiple trades at price ranging from $43.13 to $44.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 19:51 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001593968-22-001437 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 18:30 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001341 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,654 Underlying: Common Stock · 10,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 18:30 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 10,000 | $48.60 | $485,957.00 |
DisclosureSEC source: 0001593968-22-001341 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,199 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F2 · price: This transaction was executed in multiple trades at price ranging from $47.70 to $49.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 18:30 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001593968-22-001341 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 17:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001593968-22-001242 · primary_01.xml · derivative · entry 5 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,654 Underlying: Common Stock · 30,000 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F5 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 17:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 30,000 | $40.44 | $1,213,194.00 |
DisclosureSEC source: 0001593968-22-001242 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,649 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021. F2 · price: This transaction was executed in multiple trades at price ranging from $40.00 to $40.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.